PETHEMAPrograma para el Tratamiento de Hemopatías Malignas
References in periodicals archive ?
Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukaemia: a joint study of the PETHEMA and GIMEMA co-operative groups.
The results come from a prospective, multicenter, randomized, stratified by conditioning regimen, double-blind study (AMENO Study) presented at the European Hematology Association (EHA) 2011 Annual Meeting in London by the Spanish groups GETH (Grupo Espanol de Trasplante Hematopoyetico y Terapia Celular) and PETHEMA (Programa de Estudio y Tratamiento de las Hemopatias Malignas).
Data from the 60 patient Phase I/II trial conducted by the PETHEMA Foundation in Spain were evaluated by the stringent European Group for Blood and Marrow Transplantation (EBMT) criteria and results are as follows:
Highlights included: -- In the long-term follow-up of a Phase II trial conducted by the PETHEMA cooperative group, VELCADE, melphalan and prednisone (VMP) demonstrated a CR rate of 43 percent, the highest rate ever reported for a melphalan prednisone (MP) combination therapy.